Balentine LLC Dexcom Inc Transaction History

Balentine LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$114.22 - $140.1 $62,935 - $77,195	551 Added 11.44%	5,369 $744,000
Q4 2023 Feb 09, 2024	BUY	$75.49 - $124.16 $363,710 - $598,202	4,818 New	4,818 $597,000
Q2 2023 Aug 14, 2023	BUY	$112.47 - $130.98 $217,854 - $253,708	1,937 New	1,937 $248,000
Q3 2020 Nov 02, 2020	SELL	$95.51 - $112.95 $15,854 - $18,749	-166 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$62.68 - $105.34 $501 - $842	8 Added 5.06%	166 $67,000
Q1 2020 May 18, 2020	BUY	$47.79 - $75.63 $1,863 - $2,949	39 Added 32.77%	158 $43,000
Q4 2019 Sep 02, 2020	BUY	$36.62 - $57.29 $4,357 - $6,817	119 New	119 $26,000
Q4 2017 Feb 14, 2018	SELL	$11.12 - $15.38 $0 - $0	0 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$11.36 - $18.98 $0 - $0	0	0 $0

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

Stay updated on Balentine LLC with notifications on news.